A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone Propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Once Daily Compared With Placebo for 8 Weeks in Adolescent and Adult Subjects With Persistent Asthma While Treated With Short Acting Beta2-agonist.
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Fiboflapon (Primary) ; Fluticasone propionate; Montelukast
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 20 Oct 2011 Actual patient number is 700 as reported by ClinicalTrials.gov.
- 14 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Aug 2011 Planned end date changed from 1 Aug 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.